|
WO2013126746A2
(en)
|
2012-02-24 |
2013-08-29 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
|
EP2888283B1
(en)
|
2012-08-24 |
2018-09-19 |
The Regents of The University of California |
Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
|
|
ME03394B
(me)
|
2013-02-22 |
2020-01-20 |
Medimmune Ltd |
Antidllз-antitelo-pbd konjugati i nihovа upotreba
|
|
AU2014312215B2
(en)
*
|
2013-08-28 |
2020-02-27 |
Abbvie Stemcentrx Llc |
Site-specific antibody conjugation methods and compositions
|
|
SG11201601416VA
(en)
|
2013-08-28 |
2016-03-30 |
Stemcentrx Inc |
Novel sez6 modulators and methods of use
|
|
EP3107576A4
(en)
|
2014-02-21 |
2017-09-06 |
Abbvie Stemcentrx LLC |
Anti-dll3 antibodies and drug conjugates for use in melanoma
|
|
MA41645A
(fr)
*
|
2015-03-04 |
2018-01-09 |
Abbvie Stemcentrx Llc |
Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
|
|
GB201506405D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506389D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506388D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Cancer Res Technology Ltd And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506407D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506402D0
(en)
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
|
GB201506394D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506393D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
GB201506399D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
SG10202002131PA
(en)
|
2015-05-21 |
2020-05-28 |
Harpoon Therapeutics Inc |
Trispecific binding proteins and methods of use
|
|
JP2018524313A
(ja)
*
|
2015-06-23 |
2018-08-30 |
バイエル ファーマ アクチエンゲゼルシャフト |
キネシンスピンドルタンパク質（ｋｓｐ）阻害剤の抗ｂ７ｈ３抗体との抗体薬物複合体
|
|
JP2018529656A
(ja)
*
|
2015-08-20 |
2018-10-11 |
アッヴィ・ステムセントルクス・エル・エル・シー |
抗ｄｌｌ３抗体薬物コンジュゲートおよび使用方法
|
|
GB201602363D0
(en)
*
|
2016-02-10 |
2016-03-23 |
Adc Therapeutics Sa And Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
MX2018010445A
(es)
|
2016-03-01 |
2019-10-17 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
Anticuerpos especificos del receptor de poliovirus humano (rvp).
|
|
WO2018005519A2
(en)
|
2016-06-27 |
2018-01-04 |
The Regents Of The University Of California |
Cancer treatment combinations
|
|
GB201617466D0
(en)
|
2016-10-14 |
2016-11-30 |
Medimmune Ltd |
Pyrrolobenzodiazepine conjugates
|
|
CA3047683C
(en)
|
2017-02-08 |
2020-03-10 |
Adc Therapeutics Sa |
Pyrrolobenzodiazepine-antibody conjugates
|
|
GB201702031D0
(en)
|
2017-02-08 |
2017-03-22 |
Medlmmune Ltd |
Pyrrolobenzodiazepine-antibody conjugates
|
|
LT3612537T
(lt)
|
2017-04-18 |
2022-10-10 |
Medimmune Limited |
Pirolobenzodiazepino konjugatai
|
|
BR112019021880A2
(pt)
|
2017-04-20 |
2020-06-02 |
Adc Therapeutics Sa |
Terapia de combinação com conjugado anticorpo anti-axl-droga
|
|
US11318211B2
(en)
|
2017-06-14 |
2022-05-03 |
Adc Therapeutics Sa |
Dosage regimes for the administration of an anti-CD19 ADC
|
|
US20210393794A1
(en)
*
|
2017-06-20 |
2021-12-23 |
Sichuan Baili Pharm Co.Ltd |
Screening of fixed-point coupling sites of cysteine-modified antibody-toxin conjugate (tdc)
|
|
LT3668874T
(lt)
|
2017-08-18 |
2022-03-25 |
Medimmune Limited |
Pirolobenzodiazepino konjugatai
|
|
IL301637B2
(en)
|
2017-09-29 |
2024-10-01 |
Daiichi Sankyo Co Ltd |
Conjugation of an antibody with a pyrrolobenzodiazepine derivative
|
|
AU2018346955B2
(en)
|
2017-10-13 |
2024-08-29 |
Harpoon Therapeutics, Inc. |
B cell maturation antigen binding proteins
|
|
JP7381478B2
(ja)
*
|
2017-10-23 |
2023-11-15 |
マブリンク ビオシオンス |
単一分子量ポリサルコシンを含むリガンド－薬物－複合体
|
|
GB201803342D0
(en)
|
2018-03-01 |
2018-04-18 |
Medimmune Ltd |
Methods
|
|
GB201806022D0
(en)
|
2018-04-12 |
2018-05-30 |
Medimmune Ltd |
Pyrrolobenzodiazepines and conjugates thereof
|
|
CN118146372A
(zh)
*
|
2018-05-08 |
2024-06-07 |
凡恩世制药(北京)有限公司 |
抗dll3抗体及其用途
|
|
CA3108289A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11911484B2
(en)
|
2018-08-02 |
2024-02-27 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
MX2021001281A
(es)
|
2018-08-02 |
2021-07-15 |
Dyne Therapeutics Inc |
Complejos dirigidos a músculos y sus usos para el tratamiento de distrofinopatías.
|
|
EP3865151A4
(en)
*
|
2018-10-10 |
2022-11-16 |
Takeda Pharmaceutical Company Limited |
METHOD OF PREPARING AN ANTIBODY-DRUG CONJUGATE
|
|
AU2019379418A1
(en)
|
2018-11-14 |
2021-06-03 |
Daiichi Sankyo Company, Limited |
Anti-CDH6 antibody-pyrrolobenzodiazepine derivative conjugate
|
|
BR112021017616A2
(pt)
|
2019-03-25 |
2021-11-09 |
Daiichi Sankyo Co Ltd |
Conjugado de derivado de anticorpo anti-her2-pirrolobenzodiazepina
|
|
WO2020196474A1
(ja)
|
2019-03-25 |
2020-10-01 |
第一三共株式会社 |
抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
|
|
TWI841715B
(zh)
|
2019-03-27 |
2024-05-11 |
日商第一三共股份有限公司 |
抗體-吡咯并苯二氮呯衍生物結合物及ｐａｒｐ抑制劑之組合及其用途
|
|
MX2022000174A
(es)
*
|
2019-07-02 |
2022-05-20 |
Us Health |
Anticuerpos monoclonales que se enlazan a egfrviii y sus usos.
|
|
AU2021213042A1
(en)
*
|
2020-01-31 |
2022-09-22 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (TfR) antibody and uses thereof
|
|
TW202227479A
(zh)
|
2020-09-02 |
2022-07-16 |
日商第一三共股份有限公司 |
新穎內－β－Ｎ－乙醯葡萄糖胺苷酶
|
|
AU2022207708A1
(en)
|
2021-01-13 |
2023-07-27 |
Daiichi Sankyo Company, Limited |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
|
US11633498B2
(en)
|
2021-07-09 |
2023-04-25 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US11648318B2
(en)
|
2021-07-09 |
2023-05-16 |
Dyne Therapeutics, Inc. |
Anti-transferrin receptor (TFR) antibody and uses thereof
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11638761B2
(en)
|
2021-07-09 |
2023-05-02 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
|
|
US11771776B2
(en)
|
2021-07-09 |
2023-10-03 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
WO2023041041A1
(en)
*
|
2021-09-17 |
2023-03-23 |
Wuxi Biologics (Shanghai) Co., Ltd. |
D3-binding molecules and uses thereof
|
|
EP4442828A1
(en)
|
2021-11-30 |
2024-10-09 |
Daiichi Sankyo Company, Limited |
Protease-cleavable masked antibodies
|
|
WO2023116861A1
(zh)
*
|
2021-12-23 |
2023-06-29 |
江苏恒瑞医药股份有限公司 |
抗dll3抗体、其抗体-药物偶联物及其医药用途
|
|
AU2023218678A1
(en)
|
2022-02-09 |
2024-08-01 |
Daiichi Sankyo Company, Limited |
Environmentally responsive masked antibody and use thereof
|
|
IL315341A
(en)
|
2022-03-02 |
2024-10-01 |
Daiichi Sankyo Co Ltd |
A method for producing a molecule containing Fc
|
|
AU2023254846A1
(en)
|
2022-04-15 |
2024-10-10 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating myotonic dystrophy
|
